Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0FJIE)

Drug Name
Ontuxizumab Drug Info
Synonyms Amatuximab
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 2 [1]
Merkel cell carcinoma 2C34 Phase 2 [1]
Soft tissue sarcoma 2B57 Phase 2 [2]
Colorectal cancer 2B91.Z Phase 1 [3]
Cross-matching ID
TTD Drug ID
DM0FJIE

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Endosialin (CD248) TTYJWT7 CD248_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Endosialin (CD248) DTT CD248 6.583 6.215 6.827 6.832
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Endosialin (CD248) DTT CD248 2.40E-173 2.18 3.53
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):380-8.